Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 and BOTOX in Glabellar Lines
NCT07756580Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of trenibotulinumtoxinE in glabellar lines (2 cohorts), sponsored by AbbVie Inc. Primary endpoint: Adverse Events at 141 days. Started Aug 2026; status: active, not recruiting.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT07756580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756580.